Comprehensive phenotyping of regulatory T cells after liver transplantation

Anna Gronert Álvarez, Paraskevi Fytili, Pothakamuri V. Suneetha, Anke R. M. Kraft, Christin Brauner, Jerome Schlue, Till Krech, Frank Lehner, Christoph Meyer‐Heithuis, Elmar Jaeckel, Juergen Klempnauer, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer – 29 November 2014 – Regulatory T cells (Tregs) play an important role in controlling alloreactivity after solid organ transplantation, but they may also impair antiviral immunity.

Use of serial assessment of disease severity and liver biopsy for indication for liver transplantation in pediatric Epstein‐Barr virus–induced fulminant hepatic failure

Atsuko Nakazawa, Natsuko Nakano, Akinari Fukuda, Seisuke Sakamoto, Ken‐Ichi Imadome, Toyoichiro Kudo, Kentaro Matsuoka, Mureo Kasahara – 28 November 2014 – The decision to perform liver transplantation (LT) in patients with Epstein‐Barr virus (EBV)–induced fulminant hepatic failure (FHF) relies on a precise assessment of laboratory and pathological findings. In this study, we analyzed clinical and laboratory data as well as the pathological features of the liver in order to evaluate the pathogenesis and the need for LT in 5 patients with EBV‐induced FHF.

Long‐term effect of HCV eradication in patients with mixed cryoglobulinemia: A prospective, controlled, open‐label, cohort study

Laura Gragnani, Elisa Fognani, Alessia Piluso, Barbara Boldrini, Teresa Urraro, Alessio Fabbrizzi, Cristina Stasi, Jessica Ranieri, Monica Monti, Umberto Arena, Claudio Iannacone, Giacomo Laffi, Anna Linda Zignego, for the MaSVE Study Group – 27 November 2014 – Limited data are available about the efficacy of antiviral treatment in hepatitis C virus (HCV)–associated mixed cryoglobulinemia (MC), especially concerning the long‐term effects of HCV eradication.

Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation

Florence Wong, Wesley Leung, Mohammed Al Beshir, Max Marquez, Eberhard L. Renner – 25 November 2014 – Hepatorenal syndrome type 1 (HRS1) is acute renal failure in the setting of advanced cirrhosis, and it results from hemodynamic derangements, which should be fully reversible after liver transplantation. However, the rate of hepatorenal syndrome (HRS) reversal and factors predicting renal outcomes after transplantation have not been fully elucidated. The aim of this study was to assess outcomes of HRS1 patients after liver transplantation and factors predicting HRS reversal.

Subscribe to